The FDA's advisory committee has recommended that vaccine manufacturers Moderna, Pfizer/BioNTech, and Novavax update their COVID-19 vaccines to better align with the JN.1 variant, which is more representative of currently circulating strains. This ensures stronger protection against dominant variants like LP.8.1. The decision mirrors a similar recommendation from the World Health Organization as the virus continues to evolve. While uncertainty exists regarding the specific JN.1 subvariant to target by fall, this move indicates a shift towards managing COVID-19 as an endemic virus, moving away from dramatically new strains.
The FDA's advisory committee unanimously recommended updating COVID-19 vaccines to target the JN.1 variant for better protection against emerging strains.
Although uncertainty remains about which specific JN.1 subvariant to choose, the recommendation reflects the virus's evolving but largely stable nature in terms of risk.
Collection
[
|
...
]